ERBB2 and invasive breast carcinoma: In summary, comprehensive utilization of non-targeted GC-MS and LC-MS metabolomics revealed metabolomic patterns linked with the therapeutic response to NAT with TCbHP regimen in HER2 + BrCa patients.